SCHEMBL4415159

SCHEMBL4415159

CCOC(=O)Cc1ccc(OCc2ccccc2C(=O)OCC)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
ALDH1A1 P00352 2/20 0.47
HPGD P15428 1/20 0.47
MAPK10 P53779 1/20 0.46
NR1H4 Q96RI1 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
ALOX5 P09917 2/20 0.45
TBXAS1 P24557 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MEN1 O00255 1/20 0.44
HSP90AA1 P07900 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
LMNA P02545 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
MAOB P27338 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL10565161 0.99 TSHR (0.49) TSHRALDH1A1HPGDMAPK10NR1H4
SCHEMBL4417759 0.93 ALDH1A1 (0.48) TSHRALDH1A1HPGDMAPK10L3MBTL1
SCHEMBL7275027 0.87 TSHR (0.53) TSHRALDH1A1MAPK10NR1H4L3MBTL1
SCHEMBL7275470 0.86 TSHR (0.51) TSHRALDH1A1MAPK10NR1H4L3MBTL1
SCHEMBL4057078 0.85 TSHR (0.57) TSHRALDH1A1MAPK10NR1H4SMN1; SMN2
SCHEMBL10565958 0.84 ALDH1A1 (0.46) TSHRALDH1A1HPGDL3MBTL1TBXAS1
SCHEMBL7274960 0.83 TSHR (0.51) TSHRALDH1A1HPGDMAPK10NR1H4
SCHEMBL10567154 0.83 MAOB (0.51) TSHRALDH1A1TBXAS1SMN1; SMN2NPC1
SCHEMBL10562286 0.83 MAOB (0.51) TSHRTBXAS1MAOBFFAR1FFAR4
SCHEMBL10565152 0.83 MAPT (0.46) ALDH1A1HPGDALOX5TBXAS1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2058294-B1 METHOD FOR PRODUCING 2-(4-METHOXYCARBONYLMETHYLPHENOXYMETHYL)BENZOIC ACID METHYL ESTER SUMITOMO CHEMICAL CO (JP) 2013-01-02 EP disclosed
EP-2058294-B1 METHOD FOR PRODUCING 2-(4-METHOXYCARBONYLMETHYLPHENOXYMETHYL)BENZOIC ACID METHYL ESTER SUMITOMO CHEMICAL CO (JP) 2013-01-02 EP disclosed
US-7687646-B2 Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof AZAD PHARMACEUTICAL INGREDIENTS, AG (CH) 2010-03-30 US disclosed
US-7687646-B2 Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof AZAD PHARMACEUTICAL INGREDIENTS, AG (CH) 2010-03-30 US disclosed
EP-2058294-A1 2-(4-METHOXYCARBONYLMETHYLPHENOXYMETHYL)BENZOIC ACID METHYL ESTER AND METHOD FOR PRODUCING THE SAME Sumitomo Chemical Company, Limited (JP) 2009-05-13 EP disclosed
EP-2058294-A1 2-(4-METHOXYCARBONYLMETHYLPHENOXYMETHYL)BENZOIC ACID METHYL ESTER AND METHOD FOR PRODUCING THE SAME Sumitomo Chemical Company, Limited (JP) 2009-05-13 EP disclosed
WO-2007110761-A2 POLYMORPHIC FORMS OF OLOPATADINE HYDROCHLORIDE AND METHODS FOR PRODUCING OLOPATADINE AND SALTS THEREOF Universität Zürich (CH) 2007-10-04 WO disclosed
US-20070232814-A1 Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof UNIVERSITAT ZURICH (CH) 2007-10-04 US disclosed
US-20070232814-A1 Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof UNIVERSITAT ZURICH (CH) 2007-10-04 US disclosed
US-4816591-A 6,11-dihydrodibenz[b,e]oxepin-acetic acids and derivatives AMERICAN HOECHST CORPORATION (US) 1989-03-28 US disclosed
US-4585788-A 6,11-dihydrodibenz[b,e]oxepin-acetic acids and derivatives AMERICAN HOECHST CORPORATION (US) 1986-04-29 US disclosed
US-4082850-A TOPICAL APPLICATION OF A 6,11-DIHYDROBENZ(B,E)OXEPIN-ALKANOIC ACID OR DERIVATIVES THEREOF AMERICAN HOECHST CORPORATION (US) 1978-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232814-A1 Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof HRH4, HRH1, HRH3 TSHR 775/4885ALDH1A1 1477/4885HPGD 839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.